RxDoctor Payments Data

Allyson Gay, NP

Psychiatric/Mental Health · Williamsville, NYNPI 1255049052

Payments from drug & device makers

$1,781in general payments, 2019–2025

Across 66 payments — averaging $26.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$451
  • E.r. Squibb & Sons, L.L.C.$249
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$245
  • AbbVie$217
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$84
  • Lundbeck LLC$81
  • plus $455 from 10 others

What the payments were for

  • Food & beverage$1,73297%
  • Education$493%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,781 in reported general payments places this provider in the 75th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Medicare billing

Part B allowed, 2024
$4,231
Medicare patients
13
Services billed
53

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lurasidone Hcl14$2,871
Alprazolam34$1,778
Aripiprazole37$1,758
Hydroxyzine Hcl35$754
Bupropion XlBupropion Hcl12$487
Sertraline Hcl61$486
Fluoxetine Hcl32$418
Prazosin Hcl35$411
Risperidone27$379
Trazodone Hcl35$360
Quetiapine Fumarate27$287
Propranolol Hcl19$277
Venlafaxine Hcl ErVenlafaxine Hcl15$272
Hydroxyzine Pamoate21$228
Buspirone Hcl26$220

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Almatica Pharma LLCSertraline Hcl$52$48661 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in Williamsville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →